Neurocrine Biosciences, Inc. (NBIX)

95.15 -1.29 (-1.34%) At close: 04:00PM EDT

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130
United States
858 617 7600
https://www.neurocrine.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 1,200

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Kevin C. Gorman Ph.D.	CEO & Director	1.58M	31.31M	1958
Mr. Matthew C. Abernethy	Chief Financial Officer	906.76k	N/A	1980
Dr. Jude Onyia Ph.D.	Chief Scientific Officer	621.66k	N/A	1965
Mr. Eric S. Benevich	Chief Commercial Officer	805k	295.52k	1965
Dr. Eiry Wyn Roberts M.D.	Chief Medical Officer	925.46k	N/A	1964
Dr. Dimitri E. Grigoriadis	Chief Research Officer	N/A	N/A	1958
Jane Sorensen	Head of Investor Relations	N/A	N/A	N/A
Mr. Darin M. Lippoldt	Chief Legal Officer & Corp. Sec.	N/A	N/A	1966
Mr. Kyle W. Gano	Chief Bus. Devel. and Strategy Officer	N/A	N/A	1973
Ms. Julie S. Cooke	Chief HR Officer	N/A	N/A	1966

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Corporate governance

Neurocrine Biosciences, Inc.’s ISS governance QualityScore as of 1 March 2023 is 3. The pillar scores are Audit: 8; Board: 1; Shareholder rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.